Skip to main content
. 2017 Jul 6;7:4792. doi: 10.1038/s41598-017-05029-1

Figure 2.

Figure 2

Increased spinal cord Src phosphorylation in cancer-induced bone pain is blocked by dasatinib. Ratios of spinal expression of phosphorylated Src (pSrc) to total Src (a,e) and phosphorylated NMDA receptor subunit 2B (pNR2B) to total NR2B (NR2B) (b,f). (a) Cancer-induced bone pain induces an increase of spinal pSrc/Src ratio expression at the time of euthanasia. Both high and low dose dasatinib significantly decreases the level of phosphorylation of Src compared to vehicle treated control. B: Representatives of Western Blot. (c) No significant changes of spinal pNR2B/NR2b ratio expression were observed between the five treatment groups at the time of euthanasia. (d) Representatives of Western Blot. (e,f): Timeline study of cancer-induced bone. No significant change in the expression of spinal pSrc/Src (e) or pNR2B/NR2B (f) is observed during development of cancer-induced bone pain in the female rat. One-way ANOVA followed by Bonferroni’s multiple comparison test. Data are displayed as mean ± SEM, n = 4–10. The blots displayed are cropped and the full-length blots are available in the Supplementary Information file.